Tag: Deudomperidone

CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference

CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week (DDW) Conference.

CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week ® Conference

CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis.

CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis

CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis.

© 2022 CinRx Pharma. All Rights Reserved.
844-531-1834 | [email protected]

SITE PAGES

CINRX IN THE NEWS

FOLLOW US

Linkedin-in Twitter
844-531-1834 | [email protected]
Linkedin-in Twitter
© 2022 CinRx Pharma. All Rights Reserved.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES